Stelvio Therapeutics is a brand that focuses on precision medicine and novel technologies in the field of oncology. Their team consists of experts in scientific creativity, clinical excellence, and professional management, which enables them to successfully commercialize innovative drug therapies and precision medicine diagnostics. With a core competency in epigenetics, Stelvio Oncology has developed a platform that identifies compounds capable of transforming cancer stem cells into benign cell types.

Their aim is to overcome mechanisms of resistance and drive differentiation for improved cancer treatments. Led by their Chief Executive Officer, Attila Hajdu, and Co-Founder, Alexey V. Terskikh, Stelvio Therapeutics strives to partner on novel technologies to achieve success in the field.

With a commitment to precision medicine and a focus on individualized approaches to treatment, Stelvio Therapeutics is dedicated to making a meaningful impact in the fight against cancer